Sonnet BioTherapeutics Holdings Inc. [NASDAQ: SONN] price surged by 48.29 percent to reach at $1.27. The company report on August 14, 2020 that Sonnet BioTherapeutics Provides Fiscal Year Third Quarter Business and Earnings Update.
Company successfully completes warrant repricing and exchange, with gross proceeds to total $10.5 million .
Company Enters Negotiation for Potential Licensing of Neuropathies Asset.
A sum of 92048559 shares traded at recent session while its average daily volume was at 2.83M shares. Sonnet BioTherapeutics Holdings Inc. shares reached a high of $4.94 and dropped to a low of $3.35 until finishing in the latest session at $3.90.
The average equity rating for SONN stock is currently 2.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Sonnet BioTherapeutics Holdings Inc. [SONN]:
The Average True Range (ATR) for Sonnet BioTherapeutics Holdings Inc. is set at 0.54, with the Price to Sales ratio for SONN stock in the period of the last 12 months amounting to 1.84.
SONN Stock Performance Analysis:
Sonnet BioTherapeutics Holdings Inc. [SONN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 43.38. With this latest performance, SONN shares gained by 33.56% in over the last four-week period, additionally sinking by -72.74% over the last 6 months – not to mention a drop of -70.59% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SONN stock in for the last two-week period is set at 63.89, with the RSI for the last a single of trading hit 72.96, and the three-weeks RSI is set at 57.57 for Sonnet BioTherapeutics Holdings Inc. [SONN]. The present Moving Average for the last 50 days of trading for this stock 3.32, while it was recorded at 2.86 for the last single week of trading, and 9.88 for the last 200 days.
Insight into Sonnet BioTherapeutics Holdings Inc. Fundamentals:
Sonnet BioTherapeutics Holdings Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.10 and a Current Ratio set at 0.10.
SONN Stock EPS
With the latest financial reports released by the company, Sonnet BioTherapeutics Holdings Inc. posted -8.84/share EPS, while the average EPS was predicted by analysts to be reported at -8.06/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -9.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SONN.
Sonnet BioTherapeutics Holdings Inc. [SONN] Insider Position Details
There are presently around $1 million, or 2.20% of SONN stock, in the hands of institutional investors. The top three institutional holders of SONN stocks are: BLACKROCK INC. with ownership of 242,035, which is approximately 58789.294% of the company’s market cap and around 6.40% of the total institutional ownership; TOWER RESEARCH CAPITAL LLC (TRC), holding 4,491 shares of the stock with an approximate value of $18000.0 in SONN stocks shares; and UBS GROUP AG, currently with $17000.0 in SONN stock with ownership of nearly New of the company’s market capitalization.
8 institutional holders increased their position in Sonnet BioTherapeutics Holdings Inc. [NASDAQ:SONN] by around 254,452 shares. Additionally, 6 investors decreased positions by around 4,249 shares, while 2 investors held positions by with 3,786 shares. The mentioned changes placed institutional holdings at 254,915 shares, according to the latest SEC report filing. SONN stock had 6 new institutional investments in for a total of 12,827 shares, while 5 institutional investors sold positions of 4,084 shares during the same period.